Adenovirus as a gene therapy vector for hematopoietic cells

Area of Science:

• Gene therapy
• Hematopoietic stem cell biology
• Virology

Background:

• Adenovirus (Adv) gene transfer is explored for hematopoietic stem cell (HSC) therapy.
• HSCs were historically poor Adv targets due to lack of receptors and Adv's nonintegrating nature.
• Controversy exists regarding Adv's ability to infect hematopoietic cells, impacting its therapeutic use.

Purpose of the Study:

• To review the conflicting data on Adv infection of HSCs.
• To discuss advancements in Adv-mediated gene transfer for HSCs.
• To examine the Adv/CD34 controversy and current developments.

Main Methods:

• Review of existing literature on Adv and HSC interactions.
• Analysis of studies employing cytokine mixtures, high multiplicities of infection, and long incubation periods.
• Evaluation of immunological and genetic modifications to Adv for enhanced HSC transduction.

Main Results:

• Evidence supports productive Adv infections in HSCs under specific conditions.
• Cytokine cocktails, high infection doses, and extended incubation enhance Adv transduction.
• Modified Adv vectors show improved gene transfer efficiency into HSCs.

Conclusions:

• Adv gene transfer to HSCs is a rapidly evolving field with growing techniques and applications.
• Overcoming initial barriers is key to realizing Adv's potential in HSC gene therapy.
• Further research into modified Adv vectors and protocols is crucial for clinical translation.